3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside
Investing in stocks with modest valuations can set investors up for some significant returns in the long run. While there is more risk involved in putting money into smaller, less-established businesses, the upside can also be considerable, potentially resulting in massive gains.
Three mid-cap stocks that may have a lot of room to rise higher in the future are Archer Aviation (NYSE: ACHR), CRISPR Therapeutics (NASDAQ: CRSP), and e.l.f. Beauty (NYSE: ELF). Here are the big risks and opportunities that come with these stocks.
Image source: Getty Images.
Source Fool.com
CRISPR Therapeutics AG Aktie
41,63 €
-1,05 %
Unentschiedenes Community-Sentiment für CRISPR Therapeutics AG mit wenigen Einschätzungen.
Das durchschnittliche Kursziel der Community für CRISPR Therapeutics AG liegt bei 200 €, was eine mehr als doppelte Steigerung zum aktuellen Kurs von 41.63 € darstellt.
